Advertisement

HindustanTimes Tue,23 Sep 2014

Bayer loses plea against cheap Indian cancer drug

AP  New Delhi, March 05, 2013
First Published: 11:54 IST(5/3/2013) | Last Updated: 12:04 IST(5/3/2013)

India's patent appeals office has rejected international drug maker Bayer AG's plea to stop an Indian company from manufacturing a cheaper generic version of a patented cancer drug.

Advertisement

The ruling passed on Monday is being hailed as an important precedent for getting inexpensive life-saving drugs to the poor.

The German company had filed an appeal against the Indian patents office's decision last year to grant a compulsory license to local drug manufacturer Natco Pharma to produce a generic version of its kidney and liver cancer treatment Nexavar.

Bayer sells a one month supply of the drug for about $5,600. Natco's version would cost Indian patients $175 a month.


Advertisement
more from New Delhi

Registering property gets more expensive as circle rates go up in Delhi

While circle rates have been increased across the board by 20% for all categories, Delhi government officials maintained that they are still quite less than the prevailing market rates at which transactions are taking place.
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved